Andexanet alfa (Ondexxya)

Status:
Do Not Prescribe (DNP), Red
Decision Date:
December 2019
 

Comments

RED:

  • NICE TA697: Andexanet alfa for reversing anti-coagulation from apixaban or rivaroxaban.  (Decision date - June 2021)

DO NOT PRESCRIBE (DNP):

  • NICE TA697for research for reversing anti-coagulation from apixaban or rivaroxaban in adults with life-threatening or uncontrolled bleeding in the skull (intracranial haemorrhage), in the form of an ongoing randomised trial mandated by the regulator.  (Decision date - June 2021)

Red Drug Classifications

  • 4: Specifically designated as “hospital only” by product licence or by DH/NICE

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app